U.S. stocks open with little chane as investors anxiously await more news on Trump's tariff plans, Nvidia's earnings and ...

Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.

Hims & Hers Health reported fourth-quarter revenue of $481.14 million, beating estimates of $470.31 million, according to ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

Morgan Stanley notes that Hims & Hers beat in Q4 and guided Q1 and calendar year 2025 revenue significantly above the Street consensus.

Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...

Hims & Hers (NYSE:HIMS) stock tumbled 20% in post-market trading Monday after the company released its Q4 earnings report and ...

Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...